Clinical, FDG-PET and Molecular Markers of Immune Checkpoint Inhibitor Response in Patients with Advanced Merkel Cell Carcinoma — Julia Dixon‐Douglas (2022) | RDL Network
Clinical, FDG-PET and Molecular Markers of Immune Checkpoint Inhibitor Response in Patients with Advanced Merkel Cell Carcinoma
Article 2022 en
Authors
JD
Julia Dixon‐Douglas
LM
Luke S. McLean
AC
Alex Caneborg
Abstract
1 min read
Merkel cell carcinoma (MCC) is a rare, highly aggressive, neuroendocrine cancer of the skin, associated with immunosuppression, Merkel cell polyoma virus (MCPyV) infection and UV-carcinogenesis.Whilst impressive and durable responses to immune checkpoint inhibitors have revolutionised the treatment of advanced MCC.
Alison M. Weppler, Andrew Pattison, Prachi Bhave, Paolo De Ieso, Jeanette Raleigh, Athena Hatzimihalis, Anthony J. Gill, Shiva Balachander, Jason Callahan, Margaret Chua, George Au‐Yeung, Grant A. McArthur, Rodney J. Hicks, Richard W. Tothill, Shahneen Sandhu
Alison M. Weppler, Prachi Bhave, Paolo De Ieso, Jeanette Raleigh, Athena Hatzimihalis, Anthony J. Gill, Shiva Balachander, Jason Callahan, Andrew Pattison, Margaret Chua, George Au‐Yeung, Grant A. McArthur, Rodney J. Hicks, Richard W. Tothill, Shahneen Sandhu
William Mullally, Andrew S. Brohl, Aisha Ghaus, Mark Shackleton, Yang Wang, Shahneen Sandhu, Jürgen Becker, Marcin Dzienis, Liam Dwyer, Jenny Lee, Adnan Khattak, Lydia Warburton, Christopher Steer, Wen Xu
David L. Kok, Annie Wang, Wen Xu, Margaret Chua, Alexander Guminski, Michael Veness, Julie R. Howle, Richard W. Tothill, Ganessan Kichendasse, Michael Poulsen, Shahneen Sandhu, Gerald B. Fogarty
Discussion(0)
No comments yet. Be the first to comment.